防篡改羟考酮制剂对阿片类使用与危害的影响:NOMAD研究主要发现
该研究评估澳大利亚2014年上市的防篡改控释羟考酮对人群阿片类使用及危害的影响。中断时间序列分析显示高剂量控释羟考酮销量下降、其他剂型销量上升,但人群层面过量、求助或治疗寻求无显著变化。哨点人群分析显示注射等篡改使用减少,且无转向海洛因或其他药物的证据。
要点
- 防篡改控释羟考酮上市后高剂量控释剂型销量下降、其他羟考酮剂型销量上升。
- 人群层面阿片类过量、求助或治疗寻求指标无显著变化。
- 哨点人群中经篡改(主要为注射)使用控释羟考酮减少,无转向海洛因或其他药物证据。
核心结论
- 该防篡改控释羟考酮制剂减少了注射药物人群对药用阿片类的篡改使用,但未影响人群层面阿片类使用或危害。
研究设计与样本
- 研究对阿片类销售数据及多个常规收集的健康数据集进行中断时间序列分析。
- 研究随访了一个篡改药用阿片类的人群队列,并分析了注射药物人群的年度调查。
- 数据来自澳大利亚新南威尔士州、南澳大利亚州和塔斯马尼亚州,采用加权Z检验的荟萃分析整合各数据源证据。
主要发现
- 人群层面高剂量控释羟考酮销量下降,其他羟考酮剂型销量上升。
- 人群层面阿片类过量、求助或治疗寻求指标无显著影响。
- 哨点人群(前瞻性队列、注射药物人群调查、监督注射设施或针具交换项目客户)荟萃分析显示经篡改(主要为注射)使用控释羟考酮减少。
- 哨点人群无转向海洛因或其他药物使用的证据。
- 研究时未获得死亡率数据纳入分析。
临床怎么用
- 防篡改制剂可能减少注射药物人群对控释羟考酮的篡改使用,但不应预期其降低人群层面阿片类危害。
局限性
- 研究时死亡率数据不可用,未能纳入分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Escalation of pharmaceutical opioid use and harm in North America is well-documented, with similar issues emerging in Australia. One response is the development of tamper-resistant formulations of opioids. A potentially tamper-resistant formulation of controlled-release oxycodone was introduced in Australia in April, 2014, rapidly replacing the non-tamper-resistant formulation. Our study is the most systematic and comprehensive examination of the impact of a new opioid formulation to date, assessing the effect of tamper-resistant formulation of controlled-release oxycodone on population-level opioid use and opioid-related harm (ie, overdose, help-seeking, and treatment-seeking); and opioid use, tampering, and preference for the tamper-resistant formulation of controlled-release oxycodone compared with other drugs or formulations among sentinel populations likely to tamper with pharmaceutical opioids. METHODS: We conducted interrupted time-series analyses of opioid sales data and multiple routinely collected health datasets, followed up a cohort of people who tamper with pharmaceutical opioids before and after the introduction of the tamper-resistant formulation of controlled-release oxycodone, and analysed annual surveys of people who inject drugs. Data were collected from several Australian states: New South Wales, South Australia, and Tasmania. Meta-analyses (weighted Z tests) were conducted to synthesise across data sources providing evidence for a given indicator. FINDINGS: At the population level, we found reduced sales of higher strengths of controlled-release oxycodone and increased sales of other oxycodone formulations. No significant effect was observed among population-level indicators of opioid overdose, or help or treatment-seeking. Mortality data were not available for inclusion at the time of our study. Meta-analyses across sentinel populations (ie, prospective cohort, surveys of people who inject drugs, and clients of supervised injecting facilities or needle and syringe programmes) indicated reduced controlled-release oxycodone use via tampering (mainly injection), with no evidence of switching to heroin or other drug use. INTERPRETATION: This formulation of controlled-release oxycodone reduced tampering with pharmaceutical opioids among people who inject drugs, but did not affect population-level opioid use or harm. FUNDING: Mundipharma Australia, the Australian Government, and the National Health and Medical Research Council.
引用
- Larance B, Dobbins T, Peacock A, et al. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. Lancet Psychiatry. 2018. PMID: 29336948. doi:10.1016/S2215-0366(18)30003-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。